112 related articles for article (PubMed ID: 37909691)
1. Enhanced chemoimmunotherapy of breast cancer in mice by apolipoprotein A1-modified doxorubicin liposomes combined with interleukin-21.
An D; He P; Liu H; Wang R; Yu X; Chen N; Guo X; Li X; Feng M
J Drug Target; 2023 Dec; 31(10):1098-1110. PubMed ID: 37909691
[No Abstract] [Full Text] [Related]
2. Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment.
An D; Yu X; Jiang L; Wang R; He P; Chen N; Guo X; Li X; Feng M
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652957
[TBL] [Abstract][Full Text] [Related]
3. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
4. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
5. MR-labelled liposomes and focused ultrasound for spatiotemporally controlled drug release in triple negative breast cancers in mice.
Amrahli M; Centelles M; Cressey P; Prusevicius M; Gedroyc W; Xu XY; So PW; Wright M; Thanou M
Nanotheranostics; 2021; 5(2):125-142. PubMed ID: 33457192
[No Abstract] [Full Text] [Related]
6. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
Dong H; Gao M; Lu L; Gui R; Fu Y
Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
9. Live Macrophage-Delivered Doxorubicin-Loaded Liposomes Effectively Treat Triple-Negative Breast Cancer.
Yang L; Zhang Y; Zhang Y; Xu Y; Li Y; Xie Z; Wang H; Lin Y; Lin Q; Gong T; Sun X; Zhang Z; Zhang L
ACS Nano; 2022 Jun; 16(6):9799-9809. PubMed ID: 35678390
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy.
Zamani P; Navashenaq JG; Teymouri M; Karimi M; Mashreghi M; Jaafari MR
Life Sci; 2020 Jul; 252():117646. PubMed ID: 32272178
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice.
Dong J; Kong L; Wang S; Xia M; Zhang Y; Wu J; Yang F; Zuo S; Wei J
J Exp Clin Cancer Res; 2024 Apr; 43(1):102. PubMed ID: 38566092
[TBL] [Abstract][Full Text] [Related]
12. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation.
Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X
Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710
[TBL] [Abstract][Full Text] [Related]
13. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
Stravokefalou V; Stellas D; Karaliota S; Nagy BA; Valentin A; Bergamaschi C; Dimas K; Pavlakis GN
Front Immunol; 2022; 13():1014802. PubMed ID: 36713398
[TBL] [Abstract][Full Text] [Related]
14. Targeted treatment of triple-negative-breast cancer through pH-triggered tumour associated macrophages using smart theranostic nanoformulations.
Scialla S; Hanafy MS; Wang JL; Genicio N; Costa Da Silva M; Costa M; Oliveira-Pinto S; Baltazar F; Gallo J; Cui Z; Bañobre-López M
Int J Pharm; 2023 Feb; 632():122575. PubMed ID: 36603672
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and cardioprotection of nucleolin-targeted doxorubicin-loaded ultrasound nanobubbles in treating triple-negative breast cancer.
Fang K; Wang L; Huang H; Dong S; Guo Y
Nanotechnology; 2021 Mar; 32(24):. PubMed ID: 33690196
[TBL] [Abstract][Full Text] [Related]
16. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
17. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
18. Dual-Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple-Negative Breast Cancer.
Dong S; Bi Y; Sun X; Zhao Y; Sun R; Hao F; Sun Y; Wang Y; Li X; Deng W; Liu X; Ha J; Teng L; Gong P; Xie J; Kim BYS; Yang Z; Jiang W; Teng L
Small; 2022 Apr; 18(16):e2107690. PubMed ID: 35277914
[TBL] [Abstract][Full Text] [Related]
19. Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
Petruk N; Sousa S; Croset M; Polari L; Zlatev H; Selander K; Mönkkönen J; Clézardin P; Määttä J
Eur J Pharm Sci; 2023 Nov; 190():106571. PubMed ID: 37652236
[TBL] [Abstract][Full Text] [Related]
20. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
